We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

NDAQ:TGTX) TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 ...

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Study reveals surprising connection between common childhood virus CMV and Alzheimer's disease, offering new insights into ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand ...

NuRAN Wireless Inc. ("NuRAN" or the "Company") , a leading supplier of mobile and broadband wireless infrastructure solutions, is pleased to announce that it has received the full payment of an ...

What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector ® to ...

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...